{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006721","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.842181+00:00","generated_at":"2026-05-16T00:20:30.613909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunocore reports Q4 2025 KIMMTRAK sales of $104.5M, FY $400M; TEBE-AM data 2H 2026","bullets":["Q4 2025 KIMMTRAK net sales $104.5M (+24% YoY); FY2025 $400.0M (+29% YoY).","FY2025 net loss narrowed to $35.5M from $51.1M in 2024; cash $864.2M.","R&D spend rose to $274.9M (FY2025) on autoimmune programs and Phase 3 trials.","TEBE-AM Phase 3 enrollment complete 1H 2026; topline OS data expected 2H 2026.","PRAME and HIV clinical data presentations expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006721","json":"https://secwatch.observer/filing/0001140361-26-006721.json","markdown":"https://secwatch.observer/filing/0001140361-26-006721.md","text":"https://secwatch.observer/filing/0001140361-26-006721.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/0001140361-26-006721-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036126006721/ef20066378_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:20:30.613909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}